Table 3.

Characteristics of Patients With Improved Kidney Function After Foam Sclerotherapy

Age, y	Sex	Mutation Class	Baseline Scr, mg/dL	Baseline CLcr, mL/min	Change in CLcr, mL/mina	Time Interval, yb	Baseline Total Kidney Volume. mL	Total Kidney Volume Reduction, %c	Time Interval, yd	Change in MCIC Post-FS
30s	F	PKD1 protein-truncating	0.7	83	+13	1.56	1,071	−30	1.32	1D →1C
40s	F	PKD2	0.7	107	+24	1.91	1,798	−5	0.68	1C →1C
40s	F	No mutation detected	0.8	193	+31	1.33	972	−51	0.97	1C → 1B
30s	M	PKD1 protein-truncating	1.0	103	+11	1.84	1,807	+26	1.62	1D → 1D

Note: Conversion factor for units: Scr in mg/dL to μmol/L, ×88.4.

Abbreviations: CL_cr, measured creatinine clearance; FS, foam sclerotherapy; MCIC, Mayo Clinic imaging class; Scr, serum creatinine.

^aChange in CL_cr after sclerotherapy from most recent follow-up.

^bTime interval for the change in CL_cr.

^cChange in total kidney volume after sclerotherapy from most recent magnetic resonance imaging.

^dTime interval for the change in total kidney volume.